Surgery Partners Secures Consent for Merger-Related Amendments to Senior Notes

Surgery Partners, Inc. announced that its subsidiary, Surgery Center Holdings, obtained the required consents from noteholders for amendments to $1.225 billion in 7.250% Senior Notes due 2032. The amendments will allow Bon Secours Mercy Health, HealthSpan Partners, and related parties to become permitted holders without altering payment terms. The supplemental indenture is expected to be signed around November 24, 2026, with consent fees paid regardless of merger closure.
Surgery Partners, Inc. (Nasdaq: SGRY) announced on November 20, 2026, that its subsidiary, Surgery Center Holdings, Inc., successfully secured the required consents from noteholders to amend the terms of its $1.225 billion in 7.250% Senior Notes due 2032. The consent solicitation, which expired at 5:00 p.m. New York City time on the same day, was conducted under the terms of a Consent Solicitation Statement dated November 16, 2026, with amendments updated on November 18. The key change allows Bon Secours Mercy Health, Inc. (BSMH), HealthSpan Partners, and related entities to become permitted holders of the notes without altering their interest rate, payment schedule, or maturity date. The supplemental indenture is expected to be signed on or around November 24, 2026, contingent on the merger closing within five business days after the Merger Agreement’s End Date. The company will pay eligible noteholders a consent fee of $5.00 per $1,000 in principal regardless of whether the merger ultimately closes.
This development follows the October 23, 2026, signing of an Agreement and Plan of Merger between Surgery Partners and Spyglass Topco, LLC, with Spyglass Merger Subsidiary, Inc. serving as the acquiring entity. Under the agreement, Surgery Partners will survive as a wholly owned subsidiary of Topco after the merger. The proposed amendments are conditional on both the payment of the consent fee and the merger’s closure within the specified timeframe. The Trustee, Wilmington Trust, National Association, oversees the indenture, and S&P Global Inc. served as the information and tabulation agent for the consent process. The outcome hinges on future events: the merger must close on time, and the fee must be paid, or the amendments will not take effect.
The outcome of this consent solicitation could influence investor confidence in corporate restructuring deals involving debt instruments, particularly in healthcare-focused mergers. If the merger proceeds, the change in permitted holders may signal a shift in ownership control, potentially affecting governance and future financing decisions. The fact that consent fees are paid regardless of merger closure may be seen as a cost of doing business in complex transactions, but could also raise concerns about incentives for noteholders to support deals that may not materialize. This situation resembles past cases like the 2018 merger of Anthem and Cigna, where consent solicitations were used to adjust debt terms in anticipation of a transaction. However, unlike those cases, this one does not involve a change in payment terms, which may reduce investor resistance. The broader implication is that large healthcare companies may increasingly rely on such mechanisms to facilitate mergers without renegotiating core debt obligations. What remains uncertain is whether the merger will close on time, and how market participants will interpret the $5.00 fee as a signal of deal likelihood. Monitoring the November 24, 2026, signing date and subsequent developments will be critical.